Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HRS-1167 (Primary) ; Tuvusertib (Primary)
  • Indications Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms DDRiver 501
  • Sponsors EMD Serono Research & Development Institute; Merck KGaA

Most Recent Events

  • 19 Dec 2025 Status changed from recruiting to active, no longer recruiting.
  • 01 Sep 2025 Planned number of patients changed from 141 to 145.
  • 31 Jul 2025 The protocol has been amended to include Module 1 part A2 which consists of Histologically or pathologically confirmed advanced or metastatic CRPC or EOC

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top